Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
| ▸ | METAP1 | P53582 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 13/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1375990 | 0.76 | METAP2 (0.41) | METAP2METAP1GRIN2B | |
| SCHEMBL2951836 | 0.73 | NPC1 (0.41) | METAP2METAP1GRIN2B | |
| SCHEMBL19553769 | 0.73 | METAP2 (0.43) | METAP2METAP1GRIN2B | |
| SCHEMBL10600439 | 0.72 | NPC1 (0.43) | METAP2METAP1GRIN2B | |
| Hydrochloric Acid SCHEMBL6821628 | 0.72 | KDM4E (0.42) | METAP2METAP1GRIN2B | |
| SCHEMBL12921851 | 0.68 | PARP1 (0.49) | METAP2METAP1GRIN2B | |
| SCHEMBL9854786 | 0.68 | GRIN2B (0.49) | GRIN2B | |
| SCHEMBL5872328 | 0.68 | METAP2 (0.37) | METAP2METAP1GRIN2B | |
| SCHEMBL8939239 | 0.68 | PARP1 (0.43) | METAP2METAP1GRIN2B | |
| SCHEMBL2388904 | 0.68 | GRIN2B (0.47) | GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| WO-2010111406-A2 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | VHL, TP53, ASAH2 | METAP2 1415/4885METAP1 2378/4885GRIN2B 4340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.